Cefadroxil monohydrate
Executive Summary
International Trade Commission grants Bristol-Myers Squibb temporary relief Jan. 10 following a recent federal circuit court determination that the company's disputed '657 patent is "likely to be sustained" ("The Pink Sheet" Dec. 18, T&G-4). The ITC issued a cease and desist order prohibiting domestic marketing of the antibiotic by Biocraft, Kalipharma and Purepac unless a bond is posted for 68% of the "entered value of the imported articles," ITC said in a notice published in the Jan. 18 Federal Register. The commission also gave a temporary limited exclusion order prohibiting foreign manufacturers from importing the product without posting bond for 68% of its value. The orders will remain effective until the ITC reaches its final determination, due March 15.